Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. - Wikidata - awgldk - TriplyDB

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

http://www.wikidata.org/entity/Q34922533

about

Linezolid versus vancomycin for skin and soft tissue infections Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

P2860

Q24186563-D9E3B9DC-8DA8-4939-9D95-CBDFBFB5B1BD Q35746176-32577AE9-DBA9-44EC-BE42-CF59A0666F5E Q36083619-176F88EE-874D-4FDE-82CA-73E0464FED33 Q37335859-B9C4DE10-D8CA-4087-90B0-409977E5358C Q38458802-F1861E95-72EC-4A38-A54D-C7F602BC9E0B Q38797012-F76B2AF6-A2C1-401D-8466-7BCA21139DC8 Q38987098-463FE50D-721E-418E-8800-76DA6C5D12C8 Q39502727-EC316756-3313-4373-8EA0-F5C6DF5ED22E Q40804939-776251F2-B8E7-4685-9699-CC6D1367CAF2 Q41907687-A6AA838B-489F-4735-9748-9D6504DC0033

P2860

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

http://www.wikidata.org/entity/Q34922533

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@ast

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@en

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@nl

type

label

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@ast

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@en

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@nl

prefLabel

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@ast

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@en

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@nl

P1433

Q34922533-8FBB4F54-A4A1-4958-975D-FAB41F4B6417

P1476

Q34922533-DE55EB44-E087-44DA-901B-49D9C31677FB

P2093

Q34922533-477CB40D-F932-499F-AE04-918728E9C816

Q34922533-4F5C2171-311D-4BA8-9DB5-F2FD92F3516B

Q34922533-5AE3CAE5-C705-40BB-AC53-32C13E96C81D

Q34922533-618A4B34-4057-466E-A2A2-2D3B222E5790

Q34922533-64DBE7D4-9353-4169-8C6A-A38ED84C4DB4

Q34922533-78A02F86-C4AF-47E6-902E-07F12210382A

Q34922533-83A59621-7636-4C2E-ABF2-6250BD223860

Q34922533-9B6C6174-3294-4CDA-A30B-B9BB608EDE9C

Q34922533-C059042B-713E-45C3-BB67-64B7C75C49C2

Q34922533-CDCEE7E7-6E0C-45AE-B1D2-DFDB6F893AF0

P2860

Q34922533-147895AA-1132-4AD8-BAC7-1742082B2FC5

Q34922533-29BBF3EE-69BA-4BDC-B5DA-E374E8954AFB

Q34922533-2DDBB98D-664A-46AC-8C65-AE2908085372

Q34922533-2FD58F62-4538-48F8-BCC6-55495FFACF1A

Q34922533-377CFCE9-1984-4B0A-93E4-F7BDF685FAAD

Q34922533-4F183B56-5A1C-42A2-9B4A-F9FA476A69A3

Q34922533-59FD4A06-73DF-4786-8D96-CF5499C1C946

Q34922533-72702E19-02C5-45CF-AE72-BC0A7261BC4E

Q34922533-84EA3B5B-9582-4943-A3B5-1FA15F79C5FF

Q34922533-9ACF4435-13CD-43F9-B36D-5B1C25433A28

P304

Q34922533-565ED2D2-89A2-4D3C-AD0E-E13DD1B27066

P31

Q34922533-89CFF491-ECB3-4075-B2B8-515DEA2C3926

P356

Q34922533-1C28D6B1-65C6-4123-A4EF-C7D78FA06253

P407

Q34922533-027ABBE5-E9D4-45E3-9DDF-61403B1E30E9

P433

Q34922533-CB343262-C5E2-4F9D-8969-FF27B4366364

P478

Q34922533-9E35172E-9197-405D-BA7F-E2179A2602FF

P577

Q34922533-7BBDD6A0-5BDE-466D-AADD-1173041E0BEE

P698

Q34922533-B80F5480-4D29-4340-8961-18F6F9DBE591

P932

Q34922533-8AB23333-AE81-4071-ADD2-1D635AAE4A8D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetic-pharmacodynami ...... and skin structure infections.

@en

P2093

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Christopher M Rubino

http://www.w3.org/2001/XMLSchema#string

Daniel K Reynolds

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

H David Friedland

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Hammel

http://www.w3.org/2001/XMLSchema#string

Paul G Ambrose

http://www.w3.org/2001/XMLSchema#string

Scott A Van Wart

http://www.w3.org/2001/XMLSchema#string

Sujata M Bhavnani

http://www.w3.org/2001/XMLSchema#string

Tatiana Khariton

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

Prediction of creatinine clearance from serum creatinine

Immune dysfunction in patients with diabetes mellitus (DM).

A formula to estimate the approximate surface area if height and weight be known. 1916.

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.

P304

372-380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02531-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25367904

http://www.w3.org/2001/XMLSchema#string

P932

4291374

http://www.w3.org/2001/XMLSchema#string